TY - JOUR T1 - Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis JF - Evidence Based Medicine JO - Evid Based Med SP - 124 LP - 124 DO - 10.1136/ebmed-2015-110198 VL - 20 IS - 4 AU - Gareth Pryce AU - David Baker Y1 - 2015/08/01 UR - http://ebm.bmj.com/content/20/4/124.abstract N2 - Commentary on: Ball S, Vickery J, Hobart J, et al. The Cannabinoid Use in Progressive Inflammatory brain disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Asess 2015;19:1–187.OpenUrlDespite the increasing number of effective disease modifying therapies for multiple sclerosis (MS), there are no effective therapies for the progressive, neurodegenerative phase of the disease. There is now abundant experimental evidence that cannabinoids and the endocannabinoid system are protective factors in animal models of MS and also other neurodegenerative conditions. This randomised controlled trial (RCT) aimed to investigate the potential neuroprotective properties of the prototypical cannabinoid Δ 9-tetrahydrocannabinol (THC) as measured by the slowing of the progressive phase … ER -